TR-1 notification of major interest in shares

TR-1 notification of major interest in shares

The full announcement is available here.

Back to Listing Previous Next

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

Investor results briefing

EKF Diagnostics announces that it will release its preliminary results for the year ended 31 December 2019 on Tuesday 24 March 2020.

TR-1: Standard form for notification of major holdings

Standard form for notification of major holdings.

EKF Diagnostics provides the following the trading update for the year ended 31 December 2019.

Trading update and performance bonuses

EKF Diagnostics provides shareholders with the following update on current trading and performance bonuses.

Preferred Partner Arrangement with Mount Sinai

EKF Diagnostics announces that it has entered into a non-exclusive Preferred Partner Arrangement with Mount Sinai Innovation Partners.

Product showcase

Copyright © 2024 | Powered by Intergage

Quick links

News and Events

Anemia and Hemoglobin testing

Diabetes and HbA1c testing

Support

Social media

EKF Diagnostics - web 50px

Please note: Not all products are available in all countries. Please check availability.

Privacy | Terms & Conditions | Terms of Sale | ESG Statement | UK Modern Slavery Act